RYTM News and Press, Rhythm Pharmaceuticals Inc. From 06/19/19

BOSTON, June 19, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the election of Jennifer Good to its Boa...

BOSTON, May 30, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that Keith Gottesdiener, M.D., Chief Exec...

Rhythm Pharmaceuticals ( RYTM ) is approaching a critical period. In Q3'19 the company is expected to report data from two phase 3 trials of its drug setmelanotide which are the major focus of this article. Setmelanotide in POMC deficiency obesity Setmelanotide is an agonist of the melanoc...

BOSTON, May 07, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that Keith Gottesdiener, M.D., Chief Exec...

Rhythm Pharmaceuticals (NASDAQ: RYTM ): Q1 GAAP EPS of -$0.84 misses by $0.08 . More news on: Rhythm Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- Announced updated clinical data from Phase 2 basket study of setmelanotide in MC4R pathway heterozygous (HET) obesity, demonstrating consistent weight and hunger responses in patients with high-impact loss-of-function (LOF) variants - - Announced strategy for further development in ...

BOSTON, April 02, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that company management will present a ...

Rhythm Pharmaceuticals (NASDAQ: RYTM ) announces positive preliminary results from an ongoing Phase 2 clinical trial evaluating setmelanotide in patients with a rare inherited metabolic disorder called melanocortin-4 receptor (MC4R) pathway heterozygous (HET) obesity. More news on: Rhyth...

-- Stratifying Enrollment of MC4R Pathway Heterozygous (HET) Patients in Phase 2 Basket Study Based on Loss-of-Function (LOF) Variants -- -- Preliminary Data Show Consistent Weight Loss and Decreases in Hunger Observed in Patients with High-Impact LOF Variants -- -- Management to ...

Rhythm Pharmaceuticals (NASDAQ: RYTM ): Q4 GAAP EPS of -$0.74  misses by $0.16 . More news on: Rhythm Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...